Frontlight ResearchEarly access
CompletedPhase 2
Preoperative Stereotactic Radiosurgery for Brain Metastases
Key facts
- Who runs it
- Centre Jean Perrin
- Where
- France8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 70 people enrolled
- Started
- 4 Feb 2021
- Ended
- 25 Nov 2025
- Type of study
- Interventional
- Treatments tested
- Preoperative SRS
- Record updated
- 4 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (29)Hide the full registry criteria
Who can take part
- ≤ 4 distinct brain metastases, one with surgical indication
- Diagnosis of primary histologically proven breast, digestive or non-small cells lung cancer
- ≤ 5 cm larger diameter
- Karnofsky performance status ≥ 70
- No contraindication for MRI
- Possibility for the patient to be treat with both surgery and stereotactic radiotherapy
- ≥ 18 years old
- Estimated overall survival ≥ 6 months according to diagnosis specific - graded prognostic assessment (DS GPA)
- Written inform consent signed
- Affiliation to the French social security system
- For women of childbearing age including those on luteinizing hormone-releasing hormone (LH-RH) agonists for ovarian suppression: inclusion negative serum pregnancy test (≤ 7 days prior to the start of preoperative stereotactic radiosurgery (SRS)
Who cannot take part
- Mass effect with deflection ≥ 5 mm from median line or hydrocephaly or compression 4th ventricle, patient neurologically unstable, need for emergency decompressive surgery
- Anti vascular endothelial growth factor (VEGF) within 6 weeks before treatment
- Non-candidate patient for surgery
- Surgical delay > 3 days compared to stereotactic radiotherapy
- Patient participating in another intervention study within 4 weeks prior to inclusion
- Lymphoma, leukaemia, multiple myeloma, germinal tumours or cerebral primary cancer
- Metastases from small-cells lung cancer, kidney cancer, melanoma or sarcoma
- History of irradiation of the encephalon in toto
- History of stereotactic radiotherapy on metastasis to be operated on
- Psychological disorder (cognitive disorders, mental alertness, etc.) or social (deprivation of liberty by judicial or administrative decision) or geographical reasons that may compromise medical monitoring of the trial or compliance with treatment
- Woman of childbearing age without effective contraception
- > 4 brain metastases
- Contraindication to anaesthesia, MRI or gadolinium injection
- Proximity of the tumour with organs at risk which do not allow the prescribed dose to be reached in the envelope
- Pregnant or breastfeeding woman
- Documented leptomeningeal injury
- Estimated survival < 6 months by DS GPA
- Patient under guardianship or curators
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
STEP is a French multicentre, prospective, non-randomized, phase II study designed to assess 6-months local control after pre-operative stereotactic radiosurgery (SRS) for patients with brain metastases
The group in the trial
- Experimental arm (all patients)Treatment being tested
Patients will receive preoperative hypofractionated stereotactic radiosurgery (SRS). According to the association of french-speaking neuro-oncologists (ANOCEF) recommendations, total dose and fractionation will be 33 Gy in 3 fractions at the isocenter, 23.1 Gy in envelope (70% isodose), i.e. 30 Gy in growth tumor volume (GTV) envelope.) Surgery will take place within 3 days of the preoperative SRS.
Treatment: Preoperative SRS
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Study to Assess Preoperative Hypofractionated Stereotactic Radiotherapy of Brain Metastases
- Publications
- Record updated
- 4 December 2025